Bisphosphonates and osteonecrosis of the jaw: A retrospective study

Endocrine Practice

Volumn 13, Issue 3, 2007, Pages 232-238

  Murad, Omar M ^a   Arora, Surender ^b   Farag, Amal F ^c   Guber, Helena A ^c  

^a is an assistant professor of nursing at Bethel College   (United States)

^b Central Utah Clinic   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; DRUG DERIVATIVE; ETIDRONIC ACID; IMIDAZOLE DERIVATIVE; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

AGED; ARTICLE; BONE DISEASE; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; HUMAN; JAW DISEASE; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDY; URBAN POPULATION;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; DIPHOSPHONATES; ETIDRONIC ACID; HUMANS; IMIDAZOLES; JAW DISEASES; MALE; MIDDLE AGED; OSTEONECROSIS; PREVALENCE; RETROSPECTIVE STUDIES; URBAN POPULATION;

EID: 34447575020     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.13.3.232     Document Type: Article

References (31)

1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-1117.
2. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63: 1567-1575.
3. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-534.
4. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust. 2005;182:413-415.
5. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Aust. 2005;182:417-418.
6. Robinson NA, Yeo JF. Bisphosphonates-a word of caution. Ann Acad Med Singapore. 2004;33(4 Suppl):48-49.
7. Wooltorton E. Patients receiving intravenous bisphosphonates should avoid invasive dental procedures. CMAJ. 2005;172:1684.
8. Gibbs SD, O'Grady J, Seymour JF, Prince HM. Bisphosphonate-induced osteonecrosis of the jaw requires early detection and intervention. Med J Aust. 2005;183: 549-550.
9. Bagan JV, Murillo J, Jimenez Y, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med. 2005;34:120-123.
10. Ficarra G, Beninati F, Rubino I, et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol. 2005;32:1123-1128.
11. Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002;32:94-124.
12. McMahon RE, Bouquot JE, Glueck CJ, Spolnik KJ, Adams WR. Osteonecrosis: a multifactorial etiology. J Oral Maxillofac Surg. 2004;62:904-905.
13. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer. 2005;104:83-93.
14. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg. 2003;61:1104-1107.
15. Melo MD, Obeid G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc. 2005;71:111-113.
16. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23:8580-8587.
17. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates [with discussion]. N Engl J Med. 2005;353:99-102.
18. Fisher JE, Rogers MJ, Halasy JM, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A. 1999;96:133-138.
19. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 2003;9:2643-2658.
20. Takaishi Y, Ikeo T, Miki T, Nishizawa Y, Morii H. Suppression of alveolar bone resorption by etidronate treatment for periodontal disease: 4- to 5-year follow-up of four patients. J Int Med Res. 2003;31:575-584.
21. El-Shinnawi UM, El-Tantawy SI. The effect of alendronate sodium on alveolar bone loss in periodontitis (clinical trial). J Int Acad Periodontol. 2003;5:5-10.
22. Rocha M, Nava LE, Vazquez de la Torre C, Sanchez-Marin F, Garay-Sevilla ME, Malacara JM. Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: a randomized, placebo-controlled trial. J Periodontol. 2001; 72:204-209.
23. Palomo L, Bissada NF, Liu J. Periodontal assessment of postmenopausal women receiving risedronate. Menopause. 2005;12:685-690.
24. Denissen H, Montanari C, Martinetti R, van Lingen A, van den Hooff A. Alveolar bone response to submerged bisphosphonate-complexed hydroxyapatite implants. J Periodontol. 2000;71:279-286.
25. Tenenbaum HC, Shelemay A, Girard B, Zohar R, Fritz PC. Bisphosphonates and periodontics: potential applications for regulation of bone mass in the periodontium and other therapeutic/diagnostic uses. J Periodontol. 2002;73:813-822.
26. Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT, Lin RM. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis: a randomized clinical study. J Bone Joint Surg Am. 2005; 87:2155-2159.
27. Agarwala S, Jain D, Joshi VR, Sule A. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip: a prospective open-label study [erratum in Rheumatology (Oxford). 2005;44:569]. Rheumatology (Oxford). 2005;44:352-359.
28. Woo SB, Hellstein JW, Kalmar JR. Narrative (corrected) review: bisphosphonates and osteonecrosis of the jaws [erratum in Ann Intern Med. 2006;145:235]. Ann Intern Med. 2006;144:753-761.
29. Schwartz HC. Osteonecrosis and bisphosphonates: correlation versus causation. J Oral Maxillofac Surg. 2004;62: 763-764.
30. Kademani D, Koka S, Lacy MQ, Rajkumar SV. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc. 2006;81:1100-1103.
31. Eiseman B, Johnson LR, Coll JR. Ultrasound measurement of mandibular arterial blood supply: techniques for defining ischemia in the pathogenesis of alveolar ridge atrophy and tooth loss in the elderly? J Oral Maxillofac Surg. 2005;63:28-35.